Incidence and risk factors for pre-eclampsia in Jos Nigeria by Musa, Jonah et al.
Incidence and risk factors for pre-eclampsia in Jos Nigeria
Jonah Musa1, Caleb Mohammed2, Amaka Ocheke3, Makswhar Kahansim3, Victor Pam3, Patrick Daru3
1.University of  Jos Faculty of  Medical Sciences.
2. Kaduna State University Faculty of  Medicine, Obstetrics and Gynaecology.
3. University of  Jos Faculty of  Medical Sciences, Obstetrics and Gynaecology.
Abstract
Objective: We sought to estimate the incidence and risk factors associated with development of  pre-eclampsia (PET) in Jos, 
Nigeria.
Methods: An open cohort study of  singleton pregnant women attending the antenatal clinic of  Jos University Teaching Hospi-
tal (JUTH), Nigeria between November 2010 and August 2011. Eligible healthy women at ≤ 20 weeks gestation were enrolled 
and followed up until delivery or development of  pre-eclampsia. Baseline demographic characteristics including weight, height 
and body mass index (BMI) were collected at enrollment. Incidence, risk factors and hazard ratios for developing PET were 
estimated with corresponding 95% confidence intervals and p-values. All statistical analyses were done with STATA version 11, 
college station, Texas, USA.
Results: A total of  2416 pregnant women were screened for eligibility out of  which 323 were eligible for inclusion. The in-
cidence of  PET was 87.9 per 1,000 pregnancies (8.8%). The significant risk factors for PET were previous history of  PET 
(RR=5.1, 95% CI: 2.2-12.1) and BMI at booking ≥ 25 kg/m2 (RR=3.9, 95% CI: 1.5-10.0).
Conclusion:  The incidence of  PET was relatively high in our cohort in Jos, Nigeria and a previous history of  the disease and 
overweight or obese pregnant women have a significant hazard of  developing the disease in the course of  gestational follow up. 
Targeting women with these characteristics for early preventive intervention and close surveillance at the antenatal booking clinic 
may help in prevention of  the disease and its complications.
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Hypertensive disorders in pregnancy affects up to 8% of  
pregnancies1 and are among the leading causes of  ma-
ternal and neonatal morbidity and mortality worldwide, 
particularly in developing countries1,2. The National 
Heart Lung and Blood Institute (NHLBI) working group 
on research on hypertension during pregnancy1 defines 
Pre-eclampsia as a clinical syndrome that occurs after 
mid-gestation (20th week of  pregnancy), characterized by 
de novo appearance of  systolic blood pressure ≥140 mm 
Hg or diastolic blood pressure of  ≥90 mm Hg, accom-
panied by new-onset proteinuria, defined as ≥300 mg per 
24 hours. Findings from a recent multicenter study in Ni-
geria showed that pre-eclampsia/eclampsia is a leading 
cause of  significant maternal morbidity and mortality in 
Nigeria3 and ongoing efforts to improve maternal mortal-
ity in Nigeria focuses on capacity building to identify early 
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features of  pre-eclampsia and addressing gaps in appro-
priate management of  the condition during pregnancy4.
Since the etiology of  pre-eclampsia is not well under-
stood and trials on prevention have been disappoint-
ing5,6, efforts at clinical prediction based on identifiable 
risk factors seems a sensible approach to surveillance 
and prevention of  complications due to pre-eclampsia 
particularly in resource-limited settings. Indeed, delays 
in diagnosis and access to effective treatment are lead-
ing factors responsible for high maternal and perinatal 
mortality from pre-eclampsia7. Additionally, studies have 
shown the significance of  prediction, prevention, diag-
nosis and treatment among the evidence-based inter-
ventions for improving maternal and perinatal outcomes 
in pre-eclampsia and other hypertensive diseases during 
pregnancy8. Clinical risk prediction research on the de-
velopment of  pre-eclampsia have focused on nulliparous 
pregnant women and identified risk factors measured at 
14-16 weeks gestation including maternal age, mean ar-
terial blood pressure, body mass index, family history of  
preeclampsia, family history of  coronary heart disease 
and maternal birth weight9. Other previously document-
ed risk factors include systolic blood pressure at entry and 
pre-pregnancy obesity10. However, most of  these studies 
were done in countries outside of  Africa and the general-
izability of  these findings to women in Nigerian settings 
may be limited.  
This study was therefore done to provide data on inci-
dence and risk factors that are predictive of  pregnant 
women developing pre-eclampsia in an antenatal setting 
of  a University Teaching Hospital in Jos, North-Central 
Nigeria, Africa. We believe these findings will contribute 
to the body of  knowledge on the epidemiology of  this 
disease and may provide valuable information for possi-
ble development of  a screening check-list and algorithm 
for triaging booked antenatal clients for close surveillance 
in order to improve ability of  antenatal care providers to 
diagnose pre-eclampsia early thereby minimizing risk of  
complications that could result in maternal and perinatal 




This prospective open-cohort study was conducted at the 
antenatal clinic of  the Jos University Teaching Hospital, 
Jos Nigeria, a tertiary academic medical and referral cen-
ter located in North-Central Nigeria. At the time of  this 
study, the standard (traditional) model of  antenatal care 
was operational i.e 4 weekly visits for the first 28 weeks; 
2 weekly visits until 36 weeks and weekly thereafter until 
delivery. Those who develop medical complications with-
in the follow up period were admitted into the antenatal 
ward for specialized care.
Study population
All pregnant women presenting at the booking visit at 
≤ 20 weeks of  gestation estimated using the last normal 
menstruation date were screened for eligibility to partici-
pate in this study. The inclusion criteria were: 1. Normal 
blood pressure measurement at the booking visit (≤ 20 
weeks of  gestation), 2. Informed consent to participate in 
the study with indicated willingness to be followed up un-
til delivery or development of  the outcome. Those with 
significant proteinuria at booking, known hypertensive 
and high blood pressure readings at ≤  20 weeks gestation 
were excluded from the study. Those who booked for an-
tenatal care after the 20th week of  gestation were excluded 
from the study. Women with chronic medical conditions 
such as kidney disease, Diabetes mellitus, Sickle cell ane-
mia were excluded.
 
Participants’ enrollment and follow up
The study was open for enrollment from November 2010 
to August, 2011. At enrollment, a detailed questionnaire 
was administered to each research participant to obtain 
data on age, parity, date of  enrollment, gestational age at 
enrollment, educational background, smoking and alco-
hol history, previous abortions, age at marriage, history 
of  infertility and previous history of  pre-eclampsia. The 
booking blood pressure, qualitative urine protein status, 
weight, and height were also documented for each partic-
ipant.  We also obtained and recorded the HIV test results 
of  each participant.  Participant’s weight was measured 
using a standard scale (Seca manufactured by Vogel and 
Halke, Hamburg, Germany) to the nearest gram.  The 
women were weighed fully clothed with shoes removed. 
Height was measured without shoes using a Stadiome-
ter (Seca manufactured by Vogel and Halke, Hamburg, 
Germany) to the nearest centimeter. Urine protein was 
qualitatively measured using a dip stick (Uripath 2 brand 
manufactured by Antec diagnostics Limited- www.an-
tecmedicalproducts.com) on a clean catch urine sample 
passed into a universal bottle.  This was done by inserting 
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the dip stick into the urine and the result read after 60 
seconds comparing it with the standards placed on the 
container of  the dip stick. The possible readings were 
as follows: Negative, Trace, +(30mg/dl), ++ (100mg/
dl), +++ (300mg/dl) and ++++(≥2000mg/dl). In this 
study, significant proteinuria was defined as qualitative 
urine protein of  ++ or more (i.e 100mg/dl). 
Blood pressure was measured with the patient seated on a 
chair. The non-dominant arm was supported at the level 
of  the heart on a table ensuring that no tight clothing 
constricts the arm. The cuff  of  the mercury sphygmoma-
nometer (Accoson brand) was placed on the arm with the 
center of  the bladder over the brachial artery. The lower 
edge of  the cuff  was placed 2-3 cm above the point of  
the pulsation of  the brachial artery. The bladder encircled 
at least 80% of  the arm. The systolic blood pressure was 
estimated by palpating the radial artery and inflating the 
cuff  until pulsation disappears. The cuff  was then de-
flated and systolic blood pressure estimated. The sphyg-
momanometer was then inflated 30mmHg above the 
estimated systolic needed to occlude the pulse. A stetho-
scope diaphragm was then placed over the brachial artery 
and deflated at a rate of  2-3 mmHg/second until regular 
tapping sounds were heard. The systolic blood pressure 
was estimated at the level when the first sound was heard 
and diastolic blood pressure was estimated at the level 
when the sound muffled (Korotkoff  phase IV) and these 
were measured to the nearest 2 mmHg.  The follow ups 
were scheduled to fit into the routine standard antenatal 
care follow up protocol for the clinic. At each follow up 
visit, blood pressure, weight and urine protein estimations 
were repeated and documented for each patient. Follow 
up was terminated at any gestational age if  the woman 
developed pre-eclampsia or delivery of  her baby with or 
without development of  pre-eclampsia.
Primary outcome measure
The primary outcome was diagnosis of  pre-eclampsia as 
defined1 during the follow up time. The follow up time 
was the period in weeks between the gestational age at 
enrollment to development of  the primary outcome or 
delivery of  baby whichever came first).
 
Data management and Statistical analysis
All data collected were entered into an excel Microsoft 
2003 template, and coded for relevant statistical analysis. 
Summary statistics were generated to compare baseline 
characteristics of  women who developed PET to those 
who did not. We estimated the incidence of  PET and 
the risk ratio of  PET for various exposure variables and 
corresponding 95% confidence intervals and p-value 
were estimated. The risk ratio and incident rate ratio for 
the development of  pre-eclampsia were comparable for 
all the exposure variables, so we reported risk ratio for 
easy interpretation. We also developed a Cox propor-
tional hazard regression model using follow up time in 
gestational weeks as a time variable and development of  
PET as a failure variable to determine the hazard ratio 
for development of  PET for various exposure variables. 
Variables with significant hazard ratio were subsequently 
included in a multivariate Cox regression model to de-
termine independent factors associated with significant 
hazards for development of  PET. Relevant Kaplan-Meier 
graphs were generated to estimate the cumulative inci-
dent probability of  developing PET. The Log-Rank test 
was used to assess equality of  failure estimates. P values 
<0.05 suggest significant differences in cumulative inci-
dent probability of  developing PET. All statistical anal-
yses were done using STATA version 11.0, College Sta-
tion, Texas, USA. Statistical significance were based on 
95% confidence interval and p value <0.05.
Ethical approval
The study protocol was approved by the Human Subjects 
Research Ethics Committee of  the Jos University Teach-
ing Hospital, Jos.
Results
During the 10 months study period (November 2010 
to August, 2011), a total of  2416 pregnant women were 
screened for eligibility at the antenatal out-patient clinic 
of  JUTH. A total of  323 pregnant women were enrolled 
and followed up during the study (Fig. 1 shows study flow 
chart with details of  enrollment). A total of  307 complet-
ed follow up and were included in the final analysis of  
incidence and risk factors for pre-eclampsia.
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Socio-demographic characteristics of  study partic-
ipants
The median age of  the cohort was 28 years with inter-
quartile range (IQR) 25-31 years. The median parity 
and gestational age at booking were 1 (IQR, 0-3) and 
15 weeks (IQR, 12-18) respectively. The median systolic 
and diastolic blood pressures at booking were 110mmHg 
(IQR, 110-120) and 70mmHg (IQR, 60-70) respectively. 
The median body weight and body mass index at book-
ing were 63.5 kg (IQR, 55-74.5) and 25.2 kg/m2 (IQR, 
22.3-28.7) respectively. Other relevant socio-demograph-
ic characteristics of  the study cohort were positive HIV 
status of  4.9% (95% CI: 2.4-7.3); Previous history of  pre-
eclampsia of  3.6% (95% CI: 1.5-5.7); previous history of  
miscarriage of  32.6% (95% CI: 26.6-38.4); and history 
of  infertility of  8.4% (95% CI: 4.1-12.6). Almost all the 
study participants (99.3%) were married. Table 1. Shows 
baseline characteristics of  the study participants who de-
veloped PET compared to those who did not develop 
PET in the cohort.
Fig. 1. Study Flow Diagram
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Incidence of  preeclampsia
Twenty seven (27) out of  the 307 normotensive women 
included in the study developed PET during the study 
period giving an incidence of  87.9 per 1,000 pregnancies 
(8.8%). The estimated 95% CI of  the incidence was 56.5 
-120.5 cases per 1,000 pregnancies booked at 20 weeks or 
lesser gestation.
Risk factors for development of  pre-eclampsia
The significant risk factors for the development of  pre-
eclampsia in the cohort were previous history of  pre-
eclampsia (RR=5.1, 95% CI: 2.2-12.1) and BMI at book-
ing of  ≥ 25 kg/m2 (RR=3.9, 95% CI: 1.5-10.0). Previous 
history of  miscarriage, HIV infection, history of  infer-
tility and parity were not significant risk factors for the 
development of  pre-eclampsia (Table 2 summarizes the 
point estimates of  risk and the associated 95% confi-
dence intervals and p-values). 
Table 1: Baseline characteristics of study participants who developed PET compared 
with those who did not develop PET during the follow up period
Variable Developed 
PET 
95% CI Did not 
Developed 
PET 
95% CI P value* 





15.6 14.3-16.8 14.8 14.4-15.2 0.3041 
Parity  1.7 1.2-2.1 1.5 1.4-1.6 0.4895 
Weight (Kg) 73.4 67.5-79.4 65.3 63.7-67.0 0.0043 
BMI (Kg/M2) 28.1 26.2-30.0 25.6 25.0-26.1 0.0159 
SBP (mmHg) 113.1 108.9-117.4 112.0 111.0-113.4 0.6375 
DBP (mmHg) 71.0 67.9-74.2 68.3 67.4-69.3 0.0970 
BMI-Body Mass Index, SBP-Systolic Blood Pressure, DBP-Diastolic Blood Pressure, Kg-Kilograms, M2-
Meter square (*independent student t-test for differences in means between two groups) 
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In a univariate Cox proportional regression model, the 
factors associated with a significant hazard of  developing 
pre-eclampsia during the gestational follow up time were 
previous history of  pre-eclampsia (HR=5.5, 95% CI: 
1.9-16.0) and BMI at booking of  ≥ 25 kg/m2 (HR=3.8, 
95% CI: 1.5-10.1). Previous history of  miscarriage, HIV 
infection, history of  infertility and parity were not signif-
icant risk factors for the development of  pre-eclampsia. 
In the final multivariate Cox regression model including 
previous history of  pre-eclampsia, BMI category ≥ 25 
kg/m2, and parity (Nulliparous); previous history of  pre-
eclampsia (HR=7.9; 95% CI: 2.5-25.0) and BMI ≥ 25 kg/
m2 (HR=4.6; 95% CI: 1.7-12.5) were independently asso-
ciated with significant hazard of  developing pre-eclamp-
sia (Table 3). 
Table 2. Cohort analysis of risk factors for development of Preeclampsia
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Similarly, Fig.2 and 3 respectively shows the Kaplan-Mei-
er failure estimates of  the cumulative incident probability 
for developing pre-eclampsia for women with history of  
previous pre-eclampsia and those with BMI ≥ 25 kg/m2 
at booking.
Table 3. Univariate and multivariate Cox regression of the factors 
associated with hazard of developing preeclampsia in the cohort
Exposure variable Unadjusted HR (95% CI) P-Value Adjusted HR (95% CI) P-value 
Previous preeclampsia 5.5 (1.9-16.0) 0.002 7.9 (2.5-25.0) 0.001 
BMI ≥ 25kg/m2 3.8 (1.5-10.1) 0.007 4.6 (1.7-12.5) 0.003 
Parity (Nulliparous) 0.9 (0.4-2.0) 0.841 1.6 (0.7-3.6) 0.281 
Previous miscarriage 0.8 (0.4-1.8) 0.585 - - 
HIV positive 1.5 (0.3-6.2) 0.601 - - 
History of infertility 2.0 (0.6-6.9) 0.253 - - 
HR (Hazard Ratio); BMI (Body Mass Index) 
Tabl  3. Univariate and multivariate Cox regr ssion of the factors 
associated with hazard of developing preeclampsia in the cohort
Exposure variable Unadjusted HR (95% CI) P-Value Adjusted HR (95% CI) P-value 
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BMI ≥ 25kg/m2 3.8 (1.5-10.1) 0.007 4.6 (1.7-12.5) 0.003 
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Fig. 2. Kaplan-Meier of cumulative incident probability of developing PET among pregnant women with previous 
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Discussion
In this single institutional open cohort study of  normo-
tensive singleton pregnant women enrolled at ≤ 20 weeks 
of  gestation, we found the incidence of  pre-eclampsia of  
8.8% or 87.9 cases per 1,000 pregnancies. We also found 
that women with previous history of  pre-eclampsia and 
body mass index of  > 25 kg/m2 estimated at ≤ 20 weeks 
of  gestation had a significantly higher risk and hazard of  
developing pre-eclampsia during the gestational follow 
up time.
The relatively high incidence in our cohort reflects the 
growing burden of  pre-eclampsia in Nigeria and most 
developing countries. The reported incidence of  pre-
eclampsia varies from one setting to another ranging be-
tween 3-5% in most industrialized countries11 and 2-10% 
world-wide12. A large multi-center cohort study of  healthy 
nulliparous women with singleton pregnancies found an 
incidence of  pre-eclampsia of  5.3%9. The variation in in-
cidence has been linked to variation in season of  study, 
gestational age at diagnosis and severity of  PET11,13. Also, 
there is generally a higher prevalence of  pre-eclampsia in 
developing countries compared to developed industrial-
ized countries of  the world with a reported prevalence 
ranging between 2% and 16.7% in Nigeria12. Our find-
ings confirm the high burden of  this significant cause 
of  maternal and neonatal morbidity and mortality in our 
population and the need to design and implement best 
strategies to improve outcome.
There are limited longitudinal studies focusing on the 
incidence of  pre-eclampsia in Nigeria. The few longi-
tudinal studies estimated the incidence of  hypertensive 
disease in pregnancy in general and also the incidence of  
pre-eclampsia. The study done in a core Northern set-
ting found an overall incidence of  hypertensive disorder 
in pregnancy of  17% and incidence of  pre-eclampsia was 
6%14. Similarly, the cohort study done in a South Western 
Nigerian population focusing on the influence of  dura-
tion of  sexual cohabitation on the risk of  hypertension 
in nulliparous parturient15 found an incidence of  28.93% 
for gestational hypertension and 4.13% for pre-eclamp-
sia. The slight variation in the incidence of  pre-eclampsia 
reported in the North-Western population of  6%14, the 
South-Western population of  4.13%15 compared to our 
finding of  8.8% in the North-Central population shows 
the diversity of  our population characteristics within the 
country. The differences could also be explained by the 
sample sizes and the fact that previous studies focused on 
nulliparous women only.
Our study included women of  all parity categories and 
unlike previous reports showing nulliparity11,16 as a signif-
icant risk factor for pre-eclampsia, our data did not show 
a significant difference in the risk of  pre-eclampsia with 
parity. The significant risk factors for the development 
of  pre-eclampsia in our cohort were previous history 
of  pre-eclampsia and a BMI ≥ 25kg/m2 estimated at ≤ 
20 weeks of  gestation. Women with previous history of  
pre-eclampsia had a five times greater risk of  developing 
PET compared to those with no prior history (RR=5.1, 
95% CI: 2.2-12.1). Studies including only nulliparous 
women will miss this important risk factor. However, 
even in nulliparous women, those with a family history 
of  pre-eclampsia have been noted to have a significant 
risk of  developing the disease9,11,17. A similar study done 
in Northern Nigeria found that previous history of  pre-
eclampsia was associated with a four-fold greater risk of  
development of  PET compared to those with no prior 
history14. Also, women who were overweight or obese at 
≤ 20 weeks gestation were about four-fold greater risk 
of  developing PET in the course of  gestation compared 
to those who were of  normal weight or underweight 
(RR=3.9, 95% CI: 1.5-10.0). 
The impact of  maternal obesity and adverse pregnancy 
outcomes have been documented18 and a recent system-
atic review and meta-analysis on maternal body mass 
index and risk of  birth and maternal health outcomes 
in low-and middle-income countries further confirms 
the attributable risk of  maternal overweight and obesity 
with adverse maternal health outcomes19. The systemat-
ic review and meta-analysis showed that compared with 
mothers with normal BMI, overweight or obese mothers 
were at increased odds of  gestational diabetes, pregnancy 
induced hypertension, pre-eclampsia, caesarean section 
and postpartum hemorrhage19. The study results sug-
gested that preventing maternal obesity in the population 
could reduce the burden of  gestational diabetes, pregnan-
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cy induced hypertension and pre-eclampsia by 14-35%19. 
Epidemiologic studies done in Nigeria have also docu-
mented that maternal obesity is a significant predictor of  
pre-eclampsia in our population14,16. Our study findings 
further lend credence for health education on pre-preg-
nancy weight control as a strategy for improving maternal 
and perinatal outcome. It also supports the practice of  
routine screening for personal history of  pre-eclampsia 
and BMI among risk factors for development of  pre-
eclampsia as recommended in the National Institute for 
Health and Clinical Excellence clinical guidelines for ante-
natal care for healthy pregnant women20. Indeed, a recent 
committee opinion of  the American College of  Obstetri-
cians and Gynecologist (ACOG) supports that screening 
for pre-eclampsia with detailed history risk assessment is 
currently the best and only recommended screening ap-
proach for pre-eclampsia21.
The risk assessment approach based on identified epi-
demiologic risk factors is important for decision making 
to implement early those interventions that are effective 
for preventing pre-eclampsia. For instance, women with 
identified risk factors for pre-eclampsia have been shown 
to benefit from early intervention with low-dose aspirin 
started at or before 16 weeks of  gestation22. This system-
atic review and meta-analysis22, demonstrated that start-
ing low-dose aspirin at ≤ 16 weeks gestation had signif-
icant reduction in pre-eclampsia by 53% with a pooled 
relative risk of  0.47, 95% confidence interval 0.34-0.65 
in the intervention compared to placebo. Low-dose as-
pirin also significantly reduce risk of  intrauterine growth 
restriction with a pooled relative risk of  0.44; 95% CI: 
0.30-0.6522. Additionally, a recent guideline issued by the 
US Preventive Service Task Force recommended the use 
of  low-dose aspirin after 12 weeks of  gestation in women 
with high risk factors for pre-eclampsia23.
It is worth noting that 32.6% of  our study cohort report-
ed past history of  miscarriage. The proportion of  preg-
nant women with this past pregnancy event was similar 
to the 29.64% documented in a previous study in South 
Western Nigeria15. Our data showed that previous history 
of  abortion/miscarriage did not significantly affect the 
risk of  developing pre-eclampsia (Table 2 and 3). Similar 
findings have been reported in Nigeria15, with previous 
history of  abortion having no significant effect on the 
hazard of  pre-eclampsia (HR=1.05, 95% CI: 0.82-1.35). 
However, sub-group analysis showed same paternity 
abortion had a significant protective effect (HR=0.71, 
95% CI: 0.55-0.93) on pre-eclampsia15. The clinical impli-
cation of  the possible epidemiologic association of  pre-
vious abortion/miscarriage with development of  pre-ec-
lampsia requires further investigation.
The major strength of  our study is the cohort design 
with longitudinal follow up data from enrollment to de-
velopment of  outcome. Although our study was done in 
a single institution in Jos Nigeria, we feel that the cosmo-
politan nature of  our clinical setting allows for general-
izability of  our findings to the population of  women in 
most North-Central region of  Nigeria. Also, given the 
large differences in incidence of  PET between the BMI 
categories, and other risk factors in our study sample, 
our sample size of  307 pregnant women who completed 
the follow up provided more than 80% statistical power 
to detect the effect sizes found in our study. We hope 
a future larger multi-center cohort study may confirm 
our findings and improve the certainty of  our statistical 
estimates. However, we acknowledge the relatively poor 
correlation between the point-of-care dipstick estimation 
of  proteinuria used in this study with the gold standard 
of  a 24-hour urine protein estimation24. Therefore, future 
studies on pre-eclampsia should use more reliable quan-
titative methods for estimation of  proteinuria other than 
the qualitative point-of-care dipstick method.
Conclusion 
We found a relatively high incidence of  PET among preg-
nant women in Jos Nigeria and previous history of  the 
disease and overweight or obese pregnant women have 
a significant hazard of  developing the condition during 
gestational follow up. Our antenatal care services should 
be organized to include a screening checklist for identifi-
cation of  pregnant women with these epidemiologic risk 
factors and others documented in the literature. Prima-
ry health care facilities should be supported to do rou-
tine screening for these risk factors and those identified 
should commence low-dose aspirin and get referred to 
secondary or tertiary health care facilities for close mon-
itoring till delivery.
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